Epidermal growth factor receptor mutations in lung adenocarcinomas: A single center study from Iran by Basi, A. et al.
Asian Pacific Journal of Cancer Prevention, Vol 19 111
DOI:10.22034/APJCP.2018.19.1.111
EGFR Mutation in Iranian NSCLC 
Asian Pac J Cancer Prev, 19 (1), 111-114 
Introduction
According to WHO, Cancer is a major leading cause 
of death worldwide, with approximately 14 million new 
cases and 8.2 million cancer related deaths. Lung cancer is 
one of the leading causes of death and responsible of 1.59 
million deaths around the world and is predicted to be the 
7th cause of death and responsible for 3% of mortalities 
by 2030 (Karbalaie Niya et al., 2017; Moradi et al., 2017; 
Siegel et al., 2016). In Iran, lung cancer ranks second and 
third as the cancer-causing death in men and women, 
respectively and has been increasing steadily in both men 
and women during the recent years (Hajmanoochehri et 
al., 2014; Rezaei et al., 2016). Non-small cell lung cancer 
(NSCLC) is the most common type of lung cancer and 
primarily occurs in elderly patients. As life expectancy will 
be better gradually, NSCLC and related social burden will 
increase, indiscriminately. In patients that have recurrent 
or metastatic tumors, chemotherapy remains the initial 
treatment of choice (Codony-Servat et al., 2016). 
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Traditional treatment with empirically chosen 
cytotoxic chemotherapeutic agents, have given small, 
but real survival benefits. Recent advances and insights 
into molecular pathogenesis of lung cancers have 
provided some novel molecular targets. This so- called 
somatic driver mutation can serve as Achilles, heels 
for tumors(Chirieac and Kobzik, 2017). Patients with 
non-small-cell lung cancer sometimes show a dramatic 
clinical response to Gefitinib or Erlotinib that are 
reversible tyrosine kinase inhibitors (TKI) specific for 
the epidermal growth factor receptor (EGFR). However, 
until April 2004, it was unclear how to identify patients 
who would benefit from these drugs. Then, two groups 
from Boston reported that EGFR gene mutations in the 
kinase domain are strongly associated with tyrosine 
kinase inhibitor sensitivity (Kashima et al., 2017; Yang 
et al., 2017).
Mutations in epidermal growth factor receptor 
(EGFR), KRAS, and anaplastic lymphoma kinase (ALK) 
are mutually exclusive in patients with NSCLC, and the 
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presence of one mutation in lieu of another can influence 
response to targeted therapy. Therefore, testing for these 
mutations and tailoring therapy accordingly is widely 
accepted as standard practice (Genestreti et al., 2017; 
Karbalaie Niya et al., 2016). The frequency of EGFR 
mutations varies from 27 to 60% in East Asians, from 8 
to 13% in Europeans, and from 12 to 16% in African and 
white Americans. Among Asian patients the incidence of 
EGFR mutations is approximately 30% compared with 7% 
among Caucasians. Even higher mutation rates (ranging 
from 47% to 64% among various East Asian countries) 
were observed in the initial study. It is worthwhile to 
keep in mind differences between mutation frequencies 
and clinical response among different ethnic populations 
while preparing local guidelines for treatment of EGFR 
mutations (Daniels et al., 2016).
The purpose of this investigation was to examine 
the frequency and characteristics of EGFR mutations 
in Iranian patients with NSCLC and to assess the 




One hundred-twenty six patients of NSCLC were 
sequentially tested for EGFR mutation. Patient’s 
demographics, history and treatment details were obtained 
from the medical records from hospitals affiliated to Iran 
University of medical sciences, Tehran, Iran. The data and 
information were collected retrospectively from a period 
of December 2010 to April 2014.
All samples were formalin fixed paraffin embedded 
(FFPE) tissues (biopsies or surgically resected specimens), 
from primary tumors and metastatic sites, were used for 
the mutation analysis. Genomic deoxyribonucleic acid 
(DNA) was extracted by previous method (Karbalaie 
Niya et al., 2016; Karbalaie Niya et al., 2017; Safarnezhad 
Tameshkel et al., 2016) and exons 18, 19, 20, and 21 of 
EGFR gene were amplified by nested polymerase chain 
reaction (PCR). The amplified PCR product was subjected 
to the direct nucleotide sequencing for the detection of 
mutations. PCR condition and protocol was used same 
as previous works (Kelly et al., 2017; Rossi et al., 2016). 
Our research ethic committee approved the study as 
the mutation analysis of EGFR is the standard practice 
that helps to optimize treatment planning. Chi-square 
analysis was used to determine the relationship between 
the levels of two categorical variables and the linear 
relationship between continuous variables. The Student’s 
t-test was used to compare the two independent groups. 
SPSS Statistics version 21 (SPSS Inc., Chicago, IL, USA) 
was used for data analysis. All tests were two- sided, and 
p-value < 0.05 was considered statistically significant.
Results
One hundred three cases out of one hundred twenty 
six cases of NSCLC were adenocarcinoma (81.7%). 
The study population consisted of 51 (49.5%) men and 
52 women (50.5%). The age of patients ranged from 34 
years to 83 years. Among all patients, 37 (35.9%) were 
smokers. Patients’ demographic characteristics are shown 
in Table 1. Out of 103 cases with adenocarcinomas, 37 
cases were current smokers or ex-smokers and 66 cases 
were never smoker. 
Mutations in the EGFR gene were found in 25 (24.3%) 
of 103 patients distributed between male patients (14 
positives, 56%) and female patients (11 positives, 44%). 
Of 25 cases with EGFR mutations, 8 patients were 
smokers (4 female patients, 4 male patients) and 17 
were non smokers (7 female patients, 10 male patients). 
Association between EGFR mutation and sex of the 
patients was not statistically significant (P =0.45). The 
most frequent EGFR mutation was detected in exon 21 
as point mutations (L858R) (15 patients; 60%), followed 
by exon 19 (10patients; 40%). 
No mutations were seen in any of the tested cases 
of squamous cell carcinoma (11 patients), large cell 
carcinoma (6 patients) and small cell carcinoma (6 
patients). The frequency of never smokers in patients with 
tumors having EGFR mutations was significantly higher 
than that observed in patients without mutations (68% 
versus 32%; p < 0. 01).
Discussion
Most patients with lung cancer have distant metastases 
or pleural effusion at the time of initial diagnosis and 
are not candidates for surgical treatment. Systemic 
chemotherapy is the preferred method of treatment in these 
patients but the efficacy of anticancer agents is limited and 
patients with advanced diseases rarely live long (Tomoda 
et al., 2016). Epidermal growth factor receptor (EGFR), 
a cell membrane receptor with tyrosine kinase activity, 
is expressed in most patients with NSCLC and plays 
a role in cellular proliferation, inhibition of apoptosis, 
angiogenesis, metastatic potential, and chemoresistance 
(Higgins et al., 2016). EGFR gene mutation can lead to 
amplification and overexpression of EGFR protein as well 
as to other carcinogenic mechanisms of EGFR tyrosine 
kinase activity disorder. In appropriate activation of EGFR 
tyrosine kinase can promote tumor angiogenesis, tumor 
cell proliferation, adhesion, invasion and metastasis. 
In theory, specific blocking of the receptors can inhibit 
tumor formation and angiogenesis, and this theory has 
been confirmed in clinical studies (Songet al., 2016; Wang 
Characteristics All patients (n=103)
Age
     Median 67
     Range 34-83
Sex No. (%)
     Male 51(49.5%)
     Female 52(50.5%)
Smoking history No. (%)
     Never 66 (64%)
     Ever 37(36%)
Table 1. Demographic Characteristics of the Study 
Population
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The genomic discoveries in EGFR and the resultant 
targeted treatment opened up a new horizon of treatment 
in lung cancer biology and therapy. Current available 
drugs that target EGFR can be divided into 2 categories: 
small-molecule EGFR tyrosine kinase inhibitor 
(TKI)-gefitinib and erlotinib and monoclonal anti-EGFR 
antibody cetuximab that have become the standard 
first-line therapy for patients with advanced NSCLC that 
harbor EGFR mutation (El Guerrab et al., 2016; Husain 
et al., 2017). EGFR mutations are currently used as 
predictive markers of clinical response to EGFR-TKIs, 
with 70% to 80% of patients deriving substantial benefit 
from these targeted therapies. This shows the clinical 
relevance of EGFR mutational status for therapeutic 
decision making in patients with advanced NSCLC 
(Gainor et al., 2016; Samuels et al., 2016).
The nature and frequencies of lung cancer driver 
mutations have been shown to be different among racial 
and ethnic groups. The rates of EGFR mutations in lung 
adenocarcinoma is also recognized to vary across ethnic 
groups with higher prevalence observed in East-Asian 
trials than in European and North American studies, and 
the response rate to TKI in patients previously treated 
with traditional chemotherapy regimens showed better 
response rate in Asian patients than that in patients of 
other ethnicities as well (Cheema et al., 2016). 
In the present study exon 21 mutations accounted 
for 60% while exon 19 mutations accounted for 40% 
of the mutations. Interestingly, no exon 18 and exon 20 
mutations were seen. As far as we know our study has 
been the first of its kind in Iran and the results showed 
that overall frequency of EGFR mutation was higher than 
western ethnics and lower than East Asian countries and 
almost equal the frequency reported by Errihani in North 
Africans (Errihani et al., 2013).
The frequency of never smokers in patients with 
tumors harboring EGFR mutations was like many other 
studies(Tissot et al., 2016; Zenke et al., 2016). We know 
that failure to enroll the appropriate number of patients 
in a study of a new diagnostic technology can lead to 
overestimates of both the sensitivity and specificity of the 
new technology and similarly in a study of a new therapy, 
it can lead to an overestimate of the effectiveness of that 
therapy, so we are conducting another study involving a 
larger number of subjects are to confirm these findings.  
In conclusion, in this first study of EGFR mutation 
frequency in Iranian population of patients with NSCLC 
we showed that the frequency of this mutation is higher 
than that western continent but lower than in East Asian 
and almost equal to Indian population and North Africans. 
Exact definition of type of mutation will add significant 
clinical value to the management of NSCLC.
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